The Diagnostic and Prognostic Significance of ARID1A and CD8+ Expression in Endometrial Hyperplasia and Endometrial Endometrioid Adenocarcinoma (Immunohistochemical study) | ||
| Benha Medical Journal | ||
| Article 301, Volume 39, Special issue (Academic), September and October 2022, Pages 294-318 PDF (1.41 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bmfj.2022.156719.1642 | ||
| Authors | ||
| Rasha Mohammed El Sawi1; Amany Hassan2; Samia Ahmed Youssef1; Hala Adel Agina3; Hanan Ahmed* 1; Enas Ibrahim4 | ||
| 1Department of Pathology, Faculty of Medicine, Benha University, Egypt | ||
| 2Department of Pathology, Faculty of Medicine, Mansoura University, Mansura, Egypt | ||
| 3Department of pathology, Faculty of Medicine, Benha university, Egypt | ||
| 4Department of Pathology, Faculty of medicine, Benha university, Egypt | ||
| Abstract | ||
| Background: Epigenetic driver mutations and tumor microenvironment could play an important and promising role in diagnosis, prognosis, and prediction of different endometrial lesions. Aim: To determine their putative diagnostic and prognostic value, this work analyzes the immunohistochemical (IHC) expression of ARID1A and CD8+ in endometrial hyperplasia (EH) and endometrioid endometrial adenocarcinoma (EEA). Material and methods: The 80 distinct endometrial lesions included in this retrospective study included (20) EH without atypia, (30) atypical EH (AEH), and (30) EEA. Clinicopathological characteristics and survival of examined cases were correlated with the IHC expression of ARID1A and CD8+. Results: ARID1A negative expression was significantly associated with EEA (46.7%) and AEH (30%), while its positivity was associated with EH without atypia cases (100%) (P | ||
| Keywords | ||
| ARID1A; CD8+; Endometrial hyperplasia; Endometrioid adenocarcinoma | ||
|
Statistics Article View: 364 PDF Download: 542 |
||
